Indian NGOs Worry About Drug Maker M&As
This article was originally published in PharmAsia News
Non-governmental organizations in India are expressing concern about the future of the country's drug-making industry if there is a spate of mergers and acquisitions. One group representing lawyers suggested public-interest issues should be considered before the government allows any company in a vital area such as medicine to be merged with another, particularly a foreign one. It said the purchase of India's largest pharmaceutical, generics maker Ranbaxy Laboratories, by a Japanese firm could cripple the country's position as a drug-production hub. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.